Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Thill

Showing results (51-60 of 165) with videos related to

Pageof 17
Sort By:
Anticancer Research|February 11, 2015
Combined treatment of breast cancer cell lines with vitamin D and COX-2 inhibitorsMarc Thill, Kathrin Reichert, Alena Woeste, et al.
Archives of Gynecology and Obstetrics|April 21, 2011
Current diagnostic modalities and clinical pitfalls in malignant secondary breast tumoursDoerte W Luedders, Hendrik von Tengg-Kobligk, Amadeus Hornemann, et al.
Surgical Oncology|December 6, 2021
Impact of demographic and perioperative risk factors on complication rates in skin-sparing/nipple-sparing mastectomy with implant-based reconstruction using titanized polypropylene mesh (TiLOOP® Bra)Viktoria Michno, Wolfram Malter, Stefan Paepke, et al.
Anticancer Research|January 4, 2012
Influence of calcitriol on prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cell linesMarc Thill, Tim Cordes, Friederike Hoellen, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 23, 2010
Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patientsMarc Thill, Dorothea Fischer, Katharina Kelling, et al.
Breast Cancer (Dove Medical Press)|August 13, 2014
Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancerJohannes Wohlrab, Nikola Bangemann, Anke Kleine-Tebbe, et al.
Future Oncology (London, England)|November 25, 2022
PERFORM: a non-interventional study assessing the patients' treatment starting with 1L palbociclib in HR+/HER2- ABCMichael Patrick Lux, Eva Diana Runkel, Esther Glastetter, et al.
Anticancer Research|July 2, 2010
Prostaglandin metabolising enzymes and PGE2 are inversely correlated with vitamin D receptor and 25(OH)2D3 in breast cancerMarc Thill, Dorothea Fischer, Friederike Hoellen, et al.
ESMO Open|September 1, 2018
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussionMatthias Preusser, Leticia De Mattos-Arruda, Marc Thill, et al.
Brachytherapy|June 21, 2014
Is oncoplastic surgery a contraindication for accelerated partial breast radiation using the interstitial multicatheter brachytherapy method?Anna-Maria Roth, Daniela Kauer-Dorner, Alexandra Resch, et al.
Pageof 17

Showing results (51-60 of 165) with videos related to

Sort By:
Pageof 17
Anticancer Research|February 11, 2015
Combined treatment of breast cancer cell lines with vitamin D and COX-2 inhibitorsMarc Thill, Kathrin Reichert, Alena Woeste, et al.
Archives of Gynecology and Obstetrics|April 21, 2011
Current diagnostic modalities and clinical pitfalls in malignant secondary breast tumoursDoerte W Luedders, Hendrik von Tengg-Kobligk, Amadeus Hornemann, et al.
Surgical Oncology|December 6, 2021
Impact of demographic and perioperative risk factors on complication rates in skin-sparing/nipple-sparing mastectomy with implant-based reconstruction using titanized polypropylene mesh (TiLOOP® Bra)Viktoria Michno, Wolfram Malter, Stefan Paepke, et al.
Anticancer Research|January 4, 2012
Influence of calcitriol on prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cell linesMarc Thill, Tim Cordes, Friederike Hoellen, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 23, 2010
Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patientsMarc Thill, Dorothea Fischer, Katharina Kelling, et al.
Breast Cancer (Dove Medical Press)|August 13, 2014
Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancerJohannes Wohlrab, Nikola Bangemann, Anke Kleine-Tebbe, et al.
Future Oncology (London, England)|November 25, 2022
PERFORM: a non-interventional study assessing the patients' treatment starting with 1L palbociclib in HR+/HER2- ABCMichael Patrick Lux, Eva Diana Runkel, Esther Glastetter, et al.
Anticancer Research|July 2, 2010
Prostaglandin metabolising enzymes and PGE2 are inversely correlated with vitamin D receptor and 25(OH)2D3 in breast cancerMarc Thill, Dorothea Fischer, Friederike Hoellen, et al.
ESMO Open|September 1, 2018
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussionMatthias Preusser, Leticia De Mattos-Arruda, Marc Thill, et al.
Brachytherapy|June 21, 2014
Is oncoplastic surgery a contraindication for accelerated partial breast radiation using the interstitial multicatheter brachytherapy method?Anna-Maria Roth, Daniela Kauer-Dorner, Alexandra Resch, et al.
Pageof 17